The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,810.00
Bid: 1,807.50
Ask: 1,808.50
Change: 10.50 (0.58%)
Spread: 1.00 (0.055%)
Open: 1,797.00
High: 1,810.00
Low: 1,792.00
Prev. Close: 1,799.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London pre-open: FTSE called to open lower ahead of Fed and BoE minutes

Wed, 20th Nov 2013 07:33

City sources predict the FTSE 100 will open around 21 points lower than yesterday's close of 6,698.01, ahead of the release of the minutes from both the Bank of England and the latest meeting of the US Federal Reserve. The Federal Open Market Committee's meeting should offer further insight behind the Fed's decision to maintain its monetary stimulus programme. Last month the Fed said it would keep interest rates near zero and its monthly $85bn bond buying programme unchanged until the economy and jobs market improved further. The President of the Federal Reserve Bank of New York said on Monday that he was "getting more hopeful" about the economic recovery, citing labour market improvements and stronger-than-expected growth in the third quarter."Given that he is typically dovish, these comments have been taken by investors as a warning that the Fed will soon begin to wind down its asset purchase program," said Craig Erlam, Market Analyst at Alpari UK, yesterday.This morning he added: "It was no surprise when the Fed left policy unchanged last month, but investors will be looking for hints about when policy makers intend to taper. If there is still a lot of support for tapering this year, it could lead to a December taper being heavily priced in, especially if this is paired with data that suggests the economy was unaffected by the shutdown." Elsewhere, Philadelphia Fed President Charles Plosser said the Fed should set a fixed dollar amount on its monetary easing and end bond purchases when that amount is reached."We cannot continue to play this bond-buying game by ear and risk the Fed's credibility while creating lingering uncertainty about the course of monetary policy," he said in a speech before the Risk Management Association in Philadelphia.Many economists expect the Fed to announce a tapering of quantitative easing to $70bn a month in March, although uncertainty remains.Today's agenda will also be jam packed with economic data with the release of US retail sales, manufacturing inventories and mortgage applications. Back on this side of the Pond, the Bank of England will release minutes of its interest rate decision. The central bank last month announced it would keep interest rates at 0.5% and asset purchases at £375bn. Investors will today be looking to see if the BoE has shown any signs that policy makers favour a new unemployment threshold. In company news, infrastructure investor HICL Infrastructure said net asset value rose 3.2p per share for the first half of its financial year and said the pipeline of potential new investment opportunities under evaluation remains promising. NAV per share, post-interim dividend, rose to 119.6p from 116.4p at March 31st.GlaxoSmithKline has completed the partial sale of Aspen Pharmacare, the drug company announced this morning. The group has disposed 28.2m ordinary shares in Aspen at a price of 250 South African Rand (ZAR) per share, raising gross proceeds of 7,059 ZAR.Utilities reseller Telecom Plus has completed an acquisition of Npower's gas and electricity supply businesses that catapults it into big league of UK utilities. The FTSE 250 company, which operates via the Utility Warehouse brand and uses customers as distributors, has agreed a price of £218m, which it will fund via a share placing and new debt.NR
More News
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.